Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SYRE by emailGet an email when SYRE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SYRE, unsubscribe in one click. Privacy
📣 What SYRE Says Is Next
in 2027 · “Topline induction data from Part B are expected in 2027.”
Company press release, Sep 8, 2026 · SEC filing
fourth quarter of 2026 · “Topline proof-of-concept data are expected in the fourth quarter of 2026.”
Company press release, Aug 4, 2026 · SEC filing
in 2027 · “Part B: Randomized and placebo-controlled assessment of the safety and efficacy of monotherapies and combinations, designed to provide dose-ranging data on monotherapies, proof-of-concept, and contribution of components for combinations, with induction data expected in 2027.”
Company press release, Aug 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SYRE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SYRE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.